Sleep Movement Disorders Market Analysis

Sleep Movement Disorders Market: Segmentation

The global sleep movement disorders market is segmented by drug class, types of sleep movement disorders, distribution channel and region:

Sleep Movement Disorders Market: Overview

Sleep movement disorders are abnormal movements that occur during sleep. The increasing prevalence of sleep movement disorders, especially in the developed countries of North America and Europe, creates lucrative growth opportunities for the sleep movement disorders market. Based on drug class, the global sleep movement disorders market is segmented into benzodiazepines, opioids, anticonvulsants, dopaminergic agonists, and others. Dopaminergic agents are considered the first-line treatment for restless legs syndrome. Opioids are generally reserved for patients with severe symptoms and pain.

Sleep Movement Disorders Market: Regional Outlook

Over the years, sleep movement disorders have been rising globally, where North America region is expected to contribute the maximum market share in the global sleep movement disorders market. Asia Pacific sleep movement disorders market is anticipated to grow at maximum growth rate over the forecast period. Lower cost structure and favourable medical treatment policies for foreign patients are factors boosting the demand for sleep movement disorders treatment from offshore patients, especially from the North America region. Thailand, Indonesia, and India sleep centers are providing treatment to offshore patients at cheaper prices. Whereas, low-income countries of Latin America and Middle East & Africa regions are expected to register a slow growth due to lack of basic knowledge regarding the treatment of sleep movement disorders. Lack of local clinical guidelines and public and private policies for sleep medicines are also impacting the adoption of sleep movement disorders treatment.

Sleep Movement Disorders Market: Key Players

Examples of some of the key players in the global sleep movement disorders market are Cardinal Health, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Apotex Corporation, Egalet Corporation, Allergan plc, Pfizer Inc., and others.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.